News + Resources

In a recent PULSE webinar, top experts from across the U.S. life sciences ecosystem highlighted the unique importance of mergers and acquisitions (M&A) in bringing new biopharmaceutical breakthroughs to market. The panelists broke down the complex path to market for new treatments and cures, and how M&A is critical in allowing companies of all sizes to combine the necessary resources and expertise to advance these innovations.

For nearly four decades, policymakers have prioritized bipartisan policies that incentivize investment in groundbreaking medical research – aiming to make new innovations accessible for millions of Americans.

Over the past several decades, the U.S. life sciences ecosystem has emerged as a global leader in innovation with more than 2,300 biopharmaceutical companies spanning every state. Pro-innovation mergers and acquisitions (M&A) have been a critical component of the...

Every day, life sciences innovators discover promising new therapies with the potential to transform our approach to treating life-altering or life-threatening diseases. But what lies between these initial discoveries and an FDA-approved treatment reaching patients is...

In one of the more challenging investment economies in decades, life science innovators are increasingly forced to face difficult economic headwinds and market demands in their pursuit of breakthrough treatments and cures. 

Following the public comment period on the FTC and DOJ's proposed merger guidelines, leading antitrust experts and economists expressed significant concerns about the dramatic shift in competition policy that the proposal represents. In a recent panel discussion...

A recent survey by the U.S Chamber of Commerce sheds new light on the flaws of the Federal Trade Commission (FTC) and Department of Justice’s proposed approach to review and enforcement of mergers and acquisitions (M&A).

In a sharp departure from longstanding precedent, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have proposed substantial changes to the existing guidelines and rules for antitrust enforcement.

In a sharp departure from longstanding precedent, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have proposed substantial changes to the existing guidelines and rules for antitrust enforcement.

In a recent op-ed for Politico, Ankush Khardori, an attorney and former federal prosecutor for the Department of Justice (DOJ), points out the noticeable lack of evidence behind the DOJ and Federal Trade Commissions’ (FTC) proposed merger guidelines.